Literature DB >> 11565541

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.

V Kunzmann, T Ruediger, M Hallek, H K Mueller-Hermelink, M Wilhelm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11565541     DOI： 10.1182/blood.v98.6.1991

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

Review 1.  New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.

Authors:  Folke Schriever; Dieter Huhn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma.

Authors:  Bungo Saito; Tsuyoshi Nakamaki; Daisuke Adachi; Junko Suzuki; Shigeru Tomoyasu
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

3.  Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.

Authors:  Junshik Hong; Ji Yeon Kim; Hee Kyung Ahn; Sang-Min Lee; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Jeong Yeal Ahn; Sanghui Park; Sang Pyo Lee; Dong Bok Shin; Jae Hoon Lee
Journal:  Support Care Cancer       Date:  2012-10-31       Impact factor: 3.603

4.  Beneficial effects of rituximab therapy for systemic lupus erythematosus.

Authors:  Shina Menon; Pankaj Hari; Arvind Bagga
Journal:  Indian J Pediatr       Date:  2007-01       Impact factor: 5.319

Review 5.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.